The following table provides an overview of the latest patents of Novartis International Pharmaceutical Ag that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3345602Apr 6, 2022Rapamycin Derivative For Treating Advanced Solid Tumours3
EP3351246Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis9
EP3342411Aug 21, 2019Rapamycin Derivative For Treating Pancreas Cancer10
EP3143995Dec 5, 2018A Rapamycin Derivative For Treating Lung Cancer7